tissue injury News
-
3-D Printed Biomesh Minimizes Hernia Repair Complications
Over 400,000 surgeries are conducted every year in the US alone to treat hernias, one of the most common soft tissue injuries. However, the current standard of care is a highly in?ammatory process causing visceral adhesions and postsurgical complications. To address these complications, the team at Baylor College of Medicine recently used our REGENHU bioprinter to design a 3D printed biomesh ...
By Regenhu
-
Creative Bioarray Launched New Fibroblast Cells
Creative Bioarray 24th, August, 2016, launched some new fibroblast cells, along with the new cells products launch, the company released a promotion activity, aiming for providing some discouts at the beginning of autumn semester. Fibroblasts cells play an important role in wound healing, and they exist to boost the healing process. Though, there is still much to be probed as one of the most ...
-
Preventing Workplace Soft Tissue Injuries and Cal/OSHA Requirements
If a company has experienced more than one diagnosed repetitive motion injury (RMI) within a 12 month period and the injured employees were conducting “identical” or even “similar” work, Title 8, Section 5110 of California’s Occupational Safety and Health Administration (Cal/OSHA) requires specific actions be taken. These actions include: Developing and ...
-
How is open fracture treated
Usually we will be in the fracture, combined with the coverage of the fracture site of the skin and subcutaneous soft tissue injury fracture, fracture end and the outside of the same fracture called open fracture. Open fracture is faced with commonly the place that suffer an injury is broken, its difficulty rises relatively bigger also, so, how should open fracture be dealt with after all? ...
-
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear detonation. “TP508 represents a natural product released at sites of tissue injury to ...
-
Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
-
IlluminOss Medical Receives Clearance to Expand Clinical Indications in the U.S.
IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the IlluminOss Photodynamic Bone Stabilization System has received additional clinical clearance and is now indicated by the U.S. Food and Drug Administration (FDA) for use in skeletally mature patients in the treatment of traumatic, ...
-
First Patients in the U.S. Enrolled in Biosense Webster Clinical Study To Evaluate VARIPULSE™ Catheter for Atrial Fibrillation
Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
Study findings offer a promising new direction for organ regeneration and tissue repair
Researchers identify a novel approach to enhance tissue growth Because most human tissues do not regenerate spontaneously, advances in tissue repair and organ regeneration could benefit many patients with a wide variety of medical conditions. Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber/Boston Children’s Cancer and Blood ...
-
CoNextions Medical Announces Hiring of Dan Gruppo
Dan Gruppo, the Vice President of Sales and Marketing for Stryker Upper Trauma and Extremities at Stryker Orthopaedics, Joins CoNextions Medical as Executive Vice President of Sales and Marketing as CoNextions Prepares for its anticipated FDA Clearance and the Launch of its Revolutionary CoNextions TR Device in the United States CoNextions Medical (www.conextionsmed.com) has announced that Dan ...
-
Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis
Nasal obstruction remains a challenge to the modem day rhinologist. In the evolving climate of "cost containment" and "risk-outcome analyses", office-based inferior turbinate reduction has regained popularity. This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of ...
-
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. "Ms. Kampf will provide invaluable guidance as an ...
-
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, to distribute Marizyme's DuraGraft® ...
-
JCRI Discovers the Mechanism using Canady Helios Cold Plasma to Induce Cell Death in Breast Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article ...
-
Marizyme Announces Approval for DuraGraft in India
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme's distribution partner Regency Lifesciences. India ...
-
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial ...
-
CELLVIE featured in Biocentury`s Emerging Company Profile
Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. "What Jim ...
By cellvie Inc.
-
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
For children and adolescents with chronic kidney disease (CKD), as for adults, the unmet need is high for new treatments to delay disease progression and preserve kidney function / The Phase III study FIONA will investigate the effect of finerenone in pediatric patients with CKD and severely increased proteinuria Bayer announced today the initiation of the FIONA study, a multicenter, randomized, ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you